Humanigen Inc. (HGEN) Reports Complete Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19
Go back to Humanigen Inc. (HGEN) Reports Complete Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19Central Hudson Gas & Electric 4.5% Cumulative Preferred Stock (NASDAQ: HGEN) | Delayed: 0.04 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $0.04 | 52 Week High | $4.00 | |||
Open | $0.04 | 52 Week Low | $4.00 | |||
Day High | $0.04 | P/E | N/A | |||
Day Low | $0.04 | EPS | $0.00 | |||
Volume | 9,571 |